Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue tumor characterized by a relatively high risk of local recurrence and low risk of metastasis. The NCCN Guidelines for DFSP provide multidisciplinary recommendations on the management of patients with this rare disease. These NCCN Guidelines Insights highlight the addition of the Principles of Pathology section, which provides recommendations on the pathologic assessment of DFSP. Because DFSP can mimic other lesions, immunohistochemical studies are often required to establish diagnosis. Cytogenetic testing for the characteristic translocation t(17;22)(q22;q13) can also be valuable in the differential diagnosis of DFSP with other histologically similar tumors. (J Natl Compr Canc Netw 2014;12:863–868)
Disclosure of Relevant Financial Relationships

Editor:

Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

CE Authors:

Deborah J. Moonan, RN, BSN, Director, Continuing Education & Grants, NCCN has disclosed that she has no relevant financial relationships.

Ann Gianola, MA, Manager, Continuing Education & Grants, NCCN has disclosed that she has no relevant financial relationships.

Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN has disclosed that she has no relevant financial relationships.

Individuals Who Provided Content Development and/or Authorship Assistance:

Christopher K. Bichakjian, MD, panel chair, has disclosed that he has no relevant financial relationships.

Nicole R. McMillian, MS, Guidelines Coordinator, has disclosed that she has no relevant financial relationships.

Karin Hoffman, RN, CCM, guidelines coordinator, has disclosed that she has no relevant financial relationships.

Maria Ho, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.

Supported by an independent educational grant from Prometheus Laboratories, Inc., and by educational grants from Bayer HealthCare, Onyx Pharmaceuticals, Inc., and Algeta US; Exelixis, Inc.; Genentech; Genomic Health, Inc.; NOVOCURE; and Merck Sharp & Dohme Corp.
Dermatofibrosarcoma Protuberans, Version 1.2014

Overview

Dermatofibrosarcoma protuberans (DFSP) is an uncommon, low-grade sarcoma of fibroblast origin with an incidence rate of 4.2 to 4.5 cases per million persons per year in the United States.\textsuperscript{1,2} Because of its slow-growing nature, definitive diagnosis is often delayed and large size at presentation is common. Although metastasis is rare, DFSP can be locally aggressive, resulting in significant morbidity. Local recurrence rates for DFSP in older studies range from 10% to 60%,\textsuperscript{3} whereas pooled data from more recent studies using wide surgical margins showed an overall recurrence rate of 7.3%.\textsuperscript{4}

NCCN has assembled a multidisciplinary panel of leading experts from NCCN Member Institutions to develop and continually update guidelines for the treatment of nonmelanoma skin cancers. The NCCN Guidelines for DFSP are an extension of these guidelines that provide specific recommendations for DFSP management. The panel

NCCN Guidelines Insights

Overview

Dermatofibrosarcoma protuberans (DFSP) is an uncommon, low-grade sarcoma of fibroblast origin with an incidence rate of 4.2 to 4.5 cases per million persons per year in the United States.\textsuperscript{1,2} Because of its slow-growing nature, definitive diagnosis is often delayed and large size at presentation is common. Although metastasis is rare, DFSP can be locally aggressive, resulting in significant morbidity. Local recurrence rates for DFSP in older studies range from 10% to 60%,\textsuperscript{3} whereas pooled data from more recent studies using wide surgical margins showed an overall recurrence rate of 7.3%.\textsuperscript{4}

NCCN has assembled a multidisciplinary panel of leading experts from NCCN Member Institutions to develop and continually update guidelines for the treatment of nonmelanoma skin cancers. The NCCN Guidelines for DFSP are an extension of these guidelines that provide specific recommendations for DFSP management. The panel

CLINICAL PRESENTATION

WORKUP

Suspicious lesion

+ H&P
+ Complete skin exam
+ Biopsy\textsuperscript{a,b}
  + H&E
  + Immunopanel (eg, CD34, factor XIIIa)
  + Note and report evidence of fibrosarcomatous change or other high-risk features\textsuperscript{c}

See Treatment (DFSP-2)

\textsuperscript{a}This tumor is frequently misdiagnosed due to inadequate tissue sampling/superficial biopsy. Punch or incisional biopsy, preferably of deeper subcutaneous layer, is strongly recommended for sufficient tissue sampling and accurate pathologic assessment. If biopsy is indeterminate or clinical suspicion remains, rebiopsy is recommended. Wide undermining is discouraged due to the difficulty of interpreting subsequent re-excisions pathologically and of preventing possible tumor seeding.

\textsuperscript{b}Principles of Pathology (DFSP-A).

\textsuperscript{c}If fibrosarcomatous changes/malignant transformations are noted, see the NCCN Guidelines for Soft Tissue Sarcoma. Multidisciplinary consultation is recommended for other high-risk features.
### PRINCIPLES OF PATHOLOGY

- The spindled cells arranged in a storiform or fascicular pattern are typically bland with minimal cytologic atypia.
- Immunohistochemistry for CD34 is mostly positive, and Factor XIIIa negative.
- Fibrosarcomatous transformation (FS-DFSP) is reflected by a higher degree of cellularity, cytologic atypia, mitotic activity (>5/10HPF), and negative CD34 immunostaining.
- Consider additional immunostaining with nestin, apolipoprotein D, and cathepsin K for equivocal lesions, or FISH or PCR for translocation of collagen type I alpha 1 (COL1A1; on 17q22) with platelet-derived growth factor Beta (PDGFβ; on 22q13) to form the oncogenic chimeric fusion gene t(17;22) (q22;q13).
- Margin control during excision may require H&E sections supplemented by CD34 immunohistochemistry.

---

1Currently, no AJCC or CAP synoptic reporting is recommended.
Dermatofibrosarcoma Protuberans, Version 1.2014

Whether high mitotic rate or evidence of fibrosarcomatous change (typically in >5% of the surgical specimen) has prognostic significance in DFSP remains unclear. Studies in the literature both support\textsuperscript{21,22} and refute\textsuperscript{21} this notion.

NCCN Recommendations

The NCCN Guidelines outline the initial workup for DFSP in the algorithm (see DFSP-1, page 865). Because metastatic disease is rare, an extensive workup is not routinely indicated unless suggestive aspects in the history and physical examination or adverse prognostic histologic features are present. Because misdiagnosis is common, the panel strongly recommends clinicians obtain sufficient tissue from a deep subcutaneous punch biopsy or incisional biopsy for accurate pathologic assessment. When the clinician’s suspicion for DFSP is high but the initial biopsy does not support the diagnosis, rebiopsy is recommended and may reveal tumor presence. Wide undermining of the skin is discouraged because it may potentially result in tumor seeding. It can also interfere with the pathologic examination of re-excisions.

The “Principles of Pathology” section is a new section providing additional guidance on the analysis, interpretation, and reporting of pathologic results (see DFSP-A, page 866). Currently, no synoptic reporting is recommended. In most cases, examination of H&E stains using light microscopy results in an unequivocal diagnosis. However, differentiation of DFSP from dermatofibroma and other fibrous tumors can be difficult at times. In these instances, immunostaining with CD34 and factor XIIIa can be valuable. Other tests that can be useful include nestin, apolipoprotein D, cathepsin K, and fluorescence in situ hybridization or polymerase chain reaction analysis for t(17;22)(q22;q13). The panel recommends that appropriate and confirmatory immunostaining be performed in all cases of suspected DFSP.

Fibrosarcomatous change and malignant transformations should be noted, because these are high-risk features that should prompt multidisciplinary consultation to optimize clinical and reconstructive outcomes.\textsuperscript{24} Clinicians should consult the NCCN Guidelines for Soft Tissue Sarcoma when fibrosarcomatous transformations are present (to view the most recent version of these guidelines, visit NCCN.org).

Conclusions

These NCCN Guidelines Insights highlight the addition of a “Principles of Pathology” section to the NCCN Guidelines for DFSP. The NCCN Guidelines are updated at least annually, and more often when new high-quality clinical data become available in the interim. The most up-to-date version of these continuously evolving guidelines is available online at NCCN.org. The recommendations in the NCCN Guidelines are based on evidence from clinical trials where available, combined with expert consensus of the panel. Independent medical judgment is required to apply these guidelines individually to provide optimal care. The physician and the patient have the responsibility to jointly explore and select the most appropriate option from among the available alternatives. When possible, consistent with NCCN philosophy, the NCCN panel strongly encourages participation in prospective clinical trials.

References


Instructions for Completion
To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/46935; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on “New Member? Sign up here” link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet.

Posttest Questions
1. Which of the following is a characteristic translocation found in DFSP?
   a. t(9;22)(q34;q11)
   b. t(15;17)(q22;q21)
   c. t(8;14)(q24;q32)
   d. t(17;22)(q22;q13)

2. DFSP is associated with a good prognosis due to frequent early diagnosis in patients.
   a. True
   b. False

3. Which of the following represents a typical immunohistochemical stain of DFSP?
   a. CD34 positive, factor XIla negative
   b. CD34 negative, factor XIla positive
   c. CD34 positive, factor XIla positive
   d. CD34 negative, factor XIla negative